At KAMBIS, we are proud to announce a significant milestone in our mission to provide the world with high-purity, standardized botanical medicine. We are currently part of a strategic partnership building a state-of-the-art EU GMP facility right here in Thailand, which is scheduled to be export-ready by Q3 2026.
This development represents a major leap forward for our operations, offering several key advantages for our international partners:
- Bypassing the GMP Middleman: By integrating the manufacturing process into our own ecosystem, we streamline the path from our facility to the global market, ensuring a more efficient and cost-effective supply chain.
- Dual-Layer Quality Assurance: This facility builds upon our existing EU GACP standards, providing a second layer of pharmaceutical-grade validation to guarantee the safety and consistency of every batch.
- Complete Chain-of-Custody Oversight: Vertical integration allows us to maintain absolute control over the product environment from the moment of harvest through to final pharmaceutical packaging, eliminating the risks associated with external handling or transportation.
Securing Your Global Supply
As we prepare to scale our 2,000 kg annual capacity into the EU GMP framework, we are focused on long-term reliability. Most of our international partners already secure their medical supply through monthly or annual volume commitments, ensuring seamless inventory continuity and price stability.
We invite you to a formal consultation to discuss how our production capacity can be tailored to support your specific requirements and long-term pharmaceutical goals.
